Webinar: Lower McGriff Clients’ MSK Surgical Spend by Up to 70% with Regenexx Corporate Program
Select the date & time that is the most convenient for you.
Why Join Us?
Orthopedic diseases cost $980 billion annually and typically make up 20% of health plan spending. Regenexx has created a new medical specialty, Interventional Orthopedics. Using precise image-guided injections of orthobiologics, this treatment replaces the need for up to 70% of elective orthopedic surgeries and saves self-funded plans up to 70% compared to individual orthopedic surgeries.
During this 30 minute educational session with Q&A, Jason Hellickson, of Regenexx Corporate, will join us in hosting a webinar for McGriff Broker Partners that walks through the Regenexx cost-savings program for self-funded employers. Key learning objectives are outlined below.
- Why is Regenexx growing so rapidly?
- Understand how Regenexx transforms MSK for self-funded employers.
- Learn how simple this is to introduce to your clients.
- The ease of implementing the benefit.
- Tools to help you introduce Regenexx.
- Live Q&A session.
Submit the form below to register for the webinar.
Jason Hellickson | Regenexx Corporate Founder
Regenexx Corporate Webinar
Lower MSK Surgical Spend by Up to 70% with Regenexx Corporate Program
Join Jason Hellickson, of Regenexx Corporate, for an overview of the Regenexx cost-savings program for self-funded employers.